πŸ‡ΊπŸ‡Έ FDA
Patent

US 8815917

DP2 antagonist and uses thereof

granted A61KA61K31/195A61P

Quick answer

US patent 8815917 (DP2 antagonist and uses thereof) held by Panmira Pharmaceuticals, LLC expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Panmira Pharmaceuticals, LLC
Grant date
Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/195, A61P, A61P11/00, A61P11/02